



The Biomarkers Consortium
Advancing Medical Science

FDG-PET Lung and Lymphoma Projects
What the Experts are Saying

Deborah Banker, Ph.D., Vice-President, Research Communications, The Leukemia & Lymphoma Society

"Streamlining the drug approval process is key to improving outcomes for blood cancer patients. We anticipate that the findings of the FDG-PET Lymphoma Project will result in a 20-week reduction in the time it will take for the FDA to approve new lymphoma drugs and eventually other cancer drugs as well."

Jeff Evelhoch, Ph.D., Director of Medical Sciences, Amgen

"Amgen is very excited about the opportunity to help support the Lung and Lymphoma FDG-PET Projects, which are designed to improve the development of cancer therapies and outcomes for cancer patients. Amgen applauds all of the public and private partners that are coming together under The new Biomarkers Consortium to accelerate disease-specific research and advance the practice of medicine — in ways that will be very meaningful to patients. Sponsorship of these patient-focused projects clearly fits our company's mission, which is to serve patients."

Karen Ferrante, M.D., Development Therapeutic Area Head for Oncology, Pfizer Inc

"FDG-PET is a break-through technology that we are already using in several of our oncology clinical development programs to enable an early assessment of tumor status. This new validation program has the potential to increase the understanding and breadth of use of the technology to help speed the flow of new oncology drugs to patients."

Richard Hargreaves, Ph.D., Vice President and Head, Department of Imaging, Merck Research Laboratories, Merck & Co., Inc.

"We are pleased to support the FNIH initiative on FDG-PET in lymphoma and lung cancer. FDG-PET reads out on a fundamental cell biological process that is modulated in health and disease and so can act as sensitive marker of drug effects. FDG-PET is already known to be an important early response indicator and has been used in many oncology drug discovery and development programs. We welcome the opportunity to participate in this validation program to test and expand the usefulness of FDG-PET as a surrogate endpoint that can bring benefit to cancer patients by supporting faster registration and earlier availability of novel oncology agents that treat lymphoma and lung cancer."

Andrew Hughes, Ph.D., M.D., Director, Discovery Medicine, AstraZeneca

“AstraZeneca is truly excited by this collaborative opportunity between industry, NCI, academia and FDA and fully supports the objectives of the Qualification of FDG-PET in lung cancer and lymphoma as a invaluable contribution to anti-cancer drug development; providing the potential to bring effective medicines to these patients more rapidly.”

John Niederhuber, M.D., Director, National Cancer Institute

“Although we are early in the development of imaging tools as biomarkers, this research holds the potential, over time, to be used not only in the diagnoses diagnosis of cancer, but in monitoring and predicting response to therapy.”

* * *

10.5.2006